You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrichlormethiazide
Accession NumberDB01021  (APRD00031)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)
Structure
Thumb
Synonyms
Naqua
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnistadinNot Available
CarvacronNot Available
Diu-HydrinNot Available
DiureseNot Available
FluitranNot Available
KubacronNot Available
MetahydrinNot Available
NaquaNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIQ58C92TUN0
CAS number133-67-5
WeightAverage: 380.656
Monoisotopic: 378.90218026
Chemical FormulaC8H8Cl3N3O4S2
InChI KeyLMJSLTNSBFUCMU-UHFFFAOYSA-N
InChI
InChI=1S/C8H8Cl3N3O4S2/c9-3-1-4-6(2-5(3)19(12,15)16)20(17,18)14-8(13-4)7(10)11/h1-2,7-8,13-14H,(H2,12,15,16)
IUPAC Name
6-chloro-3-(dichloromethyl)-1,1-dioxo-3,4-dihydro-2H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
SMILES
NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl
Pharmacology
IndicationUsed in the treatment of oedema (including that associated with heart failure) and hypertension.
Structured Indications Not Available
PharmacodynamicsTrichloromethiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Trichloromethiazide has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomer-ulonephritis, and chronic renal failure. Trichloromethiazide is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Like other thiazides, Trichloromethiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.
Mechanism of actionTrichlormethiazide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis. As a diuretic, Trichloromethiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like Trichloromethiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of Trichloromethiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.
TargetKindPharmacological actionActionsOrganismUniProt ID
Solute carrier family 12 member 1Proteinyes
inhibitor
HumanQ13621 details
Sodium/potassium-transporting ATPase subunit alpha-1Proteinyes
inhibitor
HumanP05023 details
Carbonic anhydrase 1Proteinunknown
inhibitor
HumanP00915 details
Carbonic anhydrase 2Proteinunknown
inhibitor
HumanP00918 details
Carbonic anhydrase 4Proteinunknown
inhibitor
HumanP22748 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityOral Rat LD50 = 5600 mg/kg, oral Mouse LD50 = 2600 mg/kg
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Trichlormethiazide Action PathwayDrug actionSMP00121
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Trichlormethiazide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Trichlormethiazide.Experimental, Illicit
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Trichlormethiazide.Experimental, Illicit
5-androstenedione5-androstenedione may increase the hypokalemic activities of Trichlormethiazide.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Trichlormethiazide.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Trichlormethiazide.Approved, Investigational
AcebutololTrichlormethiazide may increase the hypotensive activities of Acebutolol.Approved
AceclofenacThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Aceclofenac.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Trichlormethiazide.Withdrawn
AcetovanilloneThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Acetovanillone.Investigational
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Acetyldigitoxin.Approved
Acetylsalicylic acidThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AclidiniumThe serum concentration of Trichlormethiazide can be increased when it is combined with Aclidinium.Approved
AdapaleneThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Adapalene.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Trichlormethiazide.Experimental
AlclometasoneAlclometasone may increase the hypokalemic activities of Trichlormethiazide.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Trichlormethiazide.Experimental
AlfacalcidolTrichlormethiazide may increase the hypercalcemic activities of Alfacalcidol.Approved, Nutraceutical
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Trichlormethiazide.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Trichlormethiazide.Approved, Investigational
AliskirenTrichlormethiazide may increase the hypotensive activities of Aliskiren.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Trichlormethiazide.Approved
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Trichlormethiazide.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Trichlormethiazide.Experimental, Illicit
AlprenololAlprenolol may increase the hypotensive activities of Trichlormethiazide.Approved, Withdrawn
AmbrisentanTrichlormethiazide may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmcinonideAmcinonide may increase the hypokalemic activities of Trichlormethiazide.Approved
AmifostineTrichlormethiazide may increase the hypotensive activities of Amifostine.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Trichlormethiazide.Approved
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Trichlormethiazide.Investigational
AnisodamineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Anisodamine.Investigational
Anisotropine MethylbromideThe serum concentration of Trichlormethiazide can be increased when it is combined with Anisotropine Methylbromide.Approved
AntipyrineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Antipyrine.Approved
AnvirzelThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Anvirzel.Investigational
ApremilastThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Apremilast.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Trichlormethiazide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Trichlormethiazide.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Trichlormethiazide.Approved
Atracurium besylateThe serum concentration of Trichlormethiazide can be increased when it is combined with Atracurium besylate.Approved
AtropineThe serum concentration of Trichlormethiazide can be increased when it is combined with Atropine.Approved, Vet Approved
AzapropazoneThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Azelastine.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Trichlormethiazide.Investigational
BalsalazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Trichlormethiazide.Approved
BarbexacloneBarbexaclone may increase the orthostatic hypotensive activities of Trichlormethiazide.Experimental
BarbitalBarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.Illicit
BeclomethasoneBeclomethasone may increase the hypokalemic activities of Trichlormethiazide.Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Trichlormethiazide.Approved, Investigational
BenactyzineThe serum concentration of Trichlormethiazide can be increased when it is combined with Benactyzine.Withdrawn
BenazeprilBenazepril may increase the hypotensive activities of Trichlormethiazide.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Trichlormethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Trichlormethiazide.Withdrawn
BenoxaprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzatropineThe serum concentration of Trichlormethiazide can be increased when it is combined with Benzatropine.Approved
BepridilTrichlormethiazide may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
BetaxololBetaxolol may increase the hypotensive activities of Trichlormethiazide.Approved
BethanidineBethanidine may increase the hypotensive activities of Trichlormethiazide.Approved
Betulinic AcidThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Betulinic Acid.Investigational
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Trichlormethiazide.Experimental, Illicit, Withdrawn
BimatoprostBimatoprost may increase the hypotensive activities of Trichlormethiazide.Approved, Investigational
BiperidenThe serum concentration of Trichlormethiazide can be increased when it is combined with Biperiden.Approved
BisoprololBisoprolol may increase the hypotensive activities of Trichlormethiazide.Approved
BosentanBosentan may increase the hypotensive activities of Trichlormethiazide.Approved, Investigational
BretyliumTrichlormethiazide may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Trichlormethiazide.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Trichlormethiazide.Approved
BromfenacThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Bromfenac.Approved
BucillamineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Trichlormethiazide.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Trichlormethiazide.Withdrawn
BupranololTrichlormethiazide may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Trichlormethiazide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trichlormethiazide.Approved, Illicit, Vet Approved
CalcidiolTrichlormethiazide may increase the hypercalcemic activities of Calcidiol.Approved, Nutraceutical
CalcipotriolTrichlormethiazide may increase the hypercalcemic activities of Calcipotriol.Approved
CalcitriolTrichlormethiazide may increase the hypercalcemic activities of Calcitriol.Approved, Nutraceutical
CalciumTrichlormethiazide may decrease the excretion rate of Calcium which could result in a higher serum level.Nutraceutical
Calcium AcetateTrichlormethiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
Calcium carbonateTrichlormethiazide may decrease the excretion rate of Calcium carbonate which could result in a higher serum level.Approved
Calcium ChlorideTrichlormethiazide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved
Calcium citrateTrichlormethiazide may decrease the excretion rate of Calcium citrate which could result in a higher serum level.Approved
Calcium glubionateTrichlormethiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
Calcium GluceptateTrichlormethiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
Calcium gluconateTrichlormethiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Trichlormethiazide.Approved
CandesartanCandesartan may increase the hypotensive activities of Trichlormethiazide.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Trichlormethiazide.Experimental
CaptoprilTrichlormethiazide may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Carbamazepine.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Trichlormethiazide.Illicit, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Trichlormethiazide.Withdrawn
CarprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Trichlormethiazide.Approved
CarvedilolTrichlormethiazide may increase the hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Trichlormethiazide.Approved, Investigational
ChloroquineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
ChlorphenoxamineThe serum concentration of Trichlormethiazide can be increased when it is combined with Chlorphenoxamine.Withdrawn
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Trichlormethiazide.Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Trichlormethiazide.Approved
CholecalciferolTrichlormethiazide may increase the hypercalcemic activities of Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Trichlormethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Trichlormethiazide.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Trichlormethiazide.Experimental
CilazaprilTrichlormethiazide may increase the hypotensive activities of Cilazapril.Approved
CitalopramCitalopram may increase the hyponatremic activities of Trichlormethiazide.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
ClobetasolClobetasol may increase the hypokalemic activities of Trichlormethiazide.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Trichlormethiazide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Trichlormethiazide.Approved
ClonidineClonidine may increase the hypotensive activities of Trichlormethiazide.Approved
ClonixinThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Clonixin.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Trichlormethiazide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Trichlormethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Trichlormethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Trichlormethiazide.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Trichlormethiazide.Approved
CurcuminThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Curcumin.Investigational
CyclopentolateThe serum concentration of Trichlormethiazide can be increased when it is combined with Cyclopentolate.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Cyclophosphamide.Approved, Investigational
CyclothiazideCyclothiazide may increase the hypotensive activities of Trichlormethiazide.Approved
D-LimoneneThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with D-Limonene.Investigational
DapoxetineDapoxetine may increase the hyponatremic activities of Trichlormethiazide.Investigational
DarifenacinThe serum concentration of Trichlormethiazide can be increased when it is combined with Darifenacin.Approved, Investigational
DebrisoquinTrichlormethiazide may increase the hypotensive activities of Debrisoquin.Approved
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Trichlormethiazide.Investigational
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Trichlormethiazide.Investigational
DeserpidineTrichlormethiazide may increase the hypotensive activities of Deserpidine.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Deslanoside.Approved
DesloratadineThe serum concentration of Trichlormethiazide can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Trichlormethiazide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Trichlormethiazide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Trichlormethiazide.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the hyponatremic activities of Trichlormethiazide.Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Trichlormethiazide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Trichlormethiazide.Vet Approved
DexetimideThe serum concentration of Trichlormethiazide can be increased when it is combined with Dexetimide.Withdrawn
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Trichlormethiazide.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Trichlormethiazide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Trichlormethiazide.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Trichlormethiazide.Approved
DiazoxideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Diazoxide.Approved
DiclofenacThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DicyclomineThe serum concentration of Trichlormethiazide can be increased when it is combined with Dicyclomine.Approved
DiflorasoneDiflorasone may increase the hypokalemic activities of Trichlormethiazide.Approved
DiflunisalThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Diflunisal.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Trichlormethiazide.Approved
DifluprednateDifluprednate may increase the hypokalemic activities of Trichlormethiazide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digitoxin.Approved
DigoxinThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digoxin.Approved
DihydralazineTrichlormethiazide may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trichlormethiazide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Trichlormethiazide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Trichlormethiazide.Experimental, Illicit
DihydrotachysterolTrichlormethiazide may increase the hypercalcemic activities of Dihydrotachysterol.Approved
DiltiazemDiltiazem may increase the hypotensive activities of Trichlormethiazide.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Trichlormethiazide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Trichlormethiazide.Approved
DobutamineDobutamine may increase the hypokalemic activities of Trichlormethiazide.Approved
DofetilideTrichlormethiazide may increase the QTc-prolonging activities of Dofetilide.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Trichlormethiazide.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Trichlormethiazide.Approved
DoxercalciferolTrichlormethiazide may increase the hypercalcemic activities of Doxercalciferol.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Trichlormethiazide.Investigational
DroxicamThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Droxicam.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Trichlormethiazide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Trichlormethiazide.Approved
DuloxetineDuloxetine may increase the hyponatremic activities of Trichlormethiazide.Approved
DuvelisibThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Duvelisib.Investigational
E6201The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with E6201.Investigational
EbselenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ebselen.Investigational
EfonidipineTrichlormethiazide may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Trichlormethiazide.Approved
EnalaprilEnalapril may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
EnalaprilatTrichlormethiazide may increase the hypotensive activities of Enalaprilat.Approved
EphedraEphedra may increase the hypokalemic activities of Trichlormethiazide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Epirizole.Approved
EpoprostenolTrichlormethiazide may increase the hypotensive activities of Epoprostenol.Approved
EprosartanEprosartan may increase the hypotensive activities of Trichlormethiazide.Approved
EquileninEquilenin may increase the hypokalemic activities of Trichlormethiazide.Experimental
EquilinEquilin may increase the hypokalemic activities of Trichlormethiazide.Approved
ErgocalciferolTrichlormethiazide may increase the hypercalcemic activities of Ergocalciferol.Approved, Nutraceutical
EscitalopramEscitalopram may increase the hyponatremic activities of Trichlormethiazide.Approved, Investigational
EstroneEstrone may increase the hypokalemic activities of Trichlormethiazide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Trichlormethiazide.Approved
EtanerceptThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Etanercept.Approved, Investigational
EthanolEthanol may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved
EthopropazineThe serum concentration of Trichlormethiazide can be increased when it is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Trichlormethiazide.Approved, Illicit
EtodolacThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Etofenamate.Approved
EtoperidoneEtoperidone may increase the hyponatremic activities of Trichlormethiazide.Approved
EtoricoxibThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Trichlormethiazide.Illicit, Vet Approved
Evening primrose oilThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Evening primrose oil.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Trichlormethiazide.Approved, Investigational
exisulindThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with exisulind.Investigational
FelodipineTrichlormethiazide may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Trichlormethiazide.Approved
FenoprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Trichlormethiazide.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Trichlormethiazide.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Trichlormethiazide can be increased when it is combined with Fesoterodine.Approved
FloctafenineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Floctafenine.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Trichlormethiazide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Trichlormethiazide.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Trichlormethiazide.Approved, Investigational
FlunixinThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Flunixin.Vet Approved
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Trichlormethiazide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Trichlormethiazide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Trichlormethiazide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Trichlormethiazide.Approved
FluoxetineFluoxetine may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Trichlormethiazide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Trichlormethiazide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Trichlormethiazide.Approved
FlurbiprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Flurbiprofen.Approved, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Trichlormethiazide.Approved
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Trichlormethiazide.Approved
FluvoxamineFluvoxamine may increase the hyponatremic activities of Trichlormethiazide.Approved, Investigational
FormestaneFormestane may increase the hypokalemic activities of Trichlormethiazide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Trichlormethiazide.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Trichlormethiazide.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
Gallamine TriethiodideThe serum concentration of Trichlormethiazide can be increased when it is combined with Gallamine Triethiodide.Approved
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Trichlormethiazide.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Trichlormethiazide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Trichlormethiazide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Trichlormethiazide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Trichlormethiazide.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Trichlormethiazide.Approved
GlycopyrroniumThe serum concentration of Trichlormethiazide can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Trichlormethiazide.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Trichlormethiazide.Approved
GuanethidineTrichlormethiazide may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Trichlormethiazide.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Trichlormethiazide.Investigational
HE3286HE3286 may increase the hypokalemic activities of Trichlormethiazide.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Trichlormethiazide.Approved, Illicit
HexamethoniumThe serum concentration of Trichlormethiazide can be increased when it is combined with Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved
HigenamineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Higenamine.Investigational
HMPL-004The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with HMPL-004.Investigational
HomatropineThe serum concentration of Trichlormethiazide can be increased when it is combined with Homatropine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Trichlormethiazide.Approved
HydralazineTrichlormethiazide may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Trichlormethiazide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Trichlormethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Trichlormethiazide.Approved, Illicit
HyoscyamineThe serum concentration of Trichlormethiazide can be increased when it is combined with Hyoscyamine.Approved
IbuprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Trichlormethiazide.Approved, Investigational
ImidaprilTrichlormethiazide may increase the hypotensive activities of Imidapril.Investigational
IndacaterolIndacaterol may increase the hypokalemic activities of Trichlormethiazide.Approved
IndalpineIndalpine may increase the hyponatremic activities of Trichlormethiazide.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Trichlormethiazide.Approved
IndenololTrichlormethiazide may increase the hypotensive activities of Indenolol.Withdrawn
IndomethacinThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminTrichlormethiazide may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Trichlormethiazide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Trichlormethiazide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Trichlormethiazide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Trichlormethiazide.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Trichlormethiazide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Trichlormethiazide.Approved
Ipratropium bromideThe serum concentration of Trichlormethiazide can be increased when it is combined with Ipratropium bromide.Approved
IproclozideIproclozide may increase the hypotensive activities of Trichlormethiazide.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Trichlormethiazide.Withdrawn
IrbesartanTrichlormethiazide may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Trichlormethiazide.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Trichlormethiazide.Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Trichlormethiazide.Approved
IsoxicamThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Isoxicam.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Trichlormethiazide.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Trichlormethiazide.Investigational
IvabradineTrichlormethiazide may increase the arrhythmogenic activities of Ivabradine.Approved
KebuzoneThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Kebuzone.Experimental
KetanserinTrichlormethiazide may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Trichlormethiazide.Approved
KetoprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ketorolac.Approved
LabetalolLabetalol may increase the hypotensive activities of Trichlormethiazide.Approved
LacidipineTrichlormethiazide may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Trichlormethiazide.Approved, Investigational
LeflunomideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Trichlormethiazide.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Trichlormethiazide.Approved
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Trichlormethiazide.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Trichlormethiazide.Approved
LicoriceLicorice may increase the hypokalemic activities of Trichlormethiazide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Trichlormethiazide.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Trichlormethiazide.Approved
LisinoprilLisinopril may increase the hypotensive activities of Trichlormethiazide.Approved, Investigational
LisofyllineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Lisofylline.Investigational
LithiumTrichlormethiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Trichlormethiazide.Illicit
LofexidineTrichlormethiazide may increase the hypotensive activities of Lofexidine.Approved, Investigational
LornoxicamThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Lornoxicam.Approved
LosartanLosartan may increase the hypotensive activities of Trichlormethiazide.Approved
LoxoprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Loxoprofen.Approved
LumiracoxibThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanTrichlormethiazide may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Magnesium salicylate.Approved
ManidipineTrichlormethiazide may increase the hypotensive activities of Manidipine.Approved
MasoprocolThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Masoprocol.Approved
ME-609ME-609 may increase the hypokalemic activities of Trichlormethiazide.Investigational
MebanazineMebanazine may increase the hypotensive activities of Trichlormethiazide.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Mecamylamine.Approved
Meclofenamic acidThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Trichlormethiazide.Approved
Mefenamic acidThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Trichlormethiazide.Vet Approved
MeloxicamThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Metamizole.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Trichlormethiazide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Trichlormethiazide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Trichlormethiazide.Approved, Illicit
MethanthelineThe serum concentration of Trichlormethiazide can be increased when it is combined with Methantheline.Approved
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Trichlormethiazide.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Trichlormethiazide.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Trichlormethiazide.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
MetipranololTrichlormethiazide may increase the hypotensive activities of Metipranolol.Approved
MetixeneThe serum concentration of Trichlormethiazide can be increased when it is combined with Metixene.Approved
MetolazoneMetolazone may increase the hypotensive activities of Trichlormethiazide.Approved
MetoprololMetoprolol may increase the hypotensive activities of Trichlormethiazide.Approved, Investigational
MetyrosineTrichlormethiazide may increase the hypotensive activities of Metyrosine.Approved
MibefradilTrichlormethiazide may increase the hypotensive activities of Mibefradil.Withdrawn
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Trichlormethiazide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Trichlormethiazide.Approved
MilnacipranMilnacipran may increase the hyponatremic activities of Trichlormethiazide.Approved
MinaprineMinaprine may increase the hypotensive activities of Trichlormethiazide.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Trichlormethiazide.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Trichlormethiazide.Approved, Investigational
MizoribineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Trichlormethiazide.Approved
MoexiprilMoexipril may increase the hypotensive activities of Trichlormethiazide.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Trichlormethiazide.Approved
MometasoneMometasone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Trichlormethiazide.Approved, Investigational
MoxonidineTrichlormethiazide may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mycophenolic acid.Approved
N-butylscopolammonium bromideThe serum concentration of Trichlormethiazide can be increased when it is combined with N-butylscopolammonium bromide.Vet Approved
NabumetoneThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nabumetone.Approved
NadololTrichlormethiazide may increase the hypotensive activities of Nadolol.Approved
NafamostatThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nafamostat.Investigational
NaftifineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Naftifine.Approved
NaftopidilTrichlormethiazide may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Trichlormethiazide.Approved
NaproxenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Trichlormethiazide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Trichlormethiazide.Investigational
NCX 4016The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with NCX 4016.Investigational
NebivololTrichlormethiazide may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the hyponatremic activities of Trichlormethiazide.Approved, Withdrawn
NepafenacThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nepafenac.Approved
NialamideNialamide may increase the hypotensive activities of Trichlormethiazide.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Trichlormethiazide.Approved
NicorandilTrichlormethiazide may increase the hypotensive activities of Nicorandil.Approved
Niflumic AcidThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineTrichlormethiazide may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineTrichlormethiazide may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nimesulide.Approved, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Trichlormethiazide.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Trichlormethiazide.Approved
NitrendipineTrichlormethiazide may increase the hypotensive activities of Nitrendipine.Approved
NitroaspirinThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nitroaspirin.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Trichlormethiazide.Approved
NorepinephrineNorepinephrine may increase the hypokalemic activities of Trichlormethiazide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Trichlormethiazide.Approved, Illicit
NVA237The serum concentration of Trichlormethiazide can be increased when it is combined with NVA237.Investigational
ObinutuzumabTrichlormethiazide may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Trichlormethiazide.Withdrawn
Oleoyl estroneOleoyl estrone may increase the hypokalemic activities of Trichlormethiazide.Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Trichlormethiazide.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Trichlormethiazide.Approved
OlopatadineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Trichlormethiazide.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Trichlormethiazide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Trichlormethiazide.Approved
OrgoteinThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Orgotein.Vet Approved
OrphenadrineThe serum concentration of Trichlormethiazide can be increased when it is combined with Orphenadrine.Approved
OuabainThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Oxaprozin.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Oxcarbazepine.Approved
OxprenololTrichlormethiazide may increase the hypotensive activities of Oxprenolol.Approved
OxybutyninThe serum concentration of Trichlormethiazide can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trichlormethiazide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Trichlormethiazide.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Oxyphenbutazone.Withdrawn
OxyphenoniumThe serum concentration of Trichlormethiazide can be increased when it is combined with Oxyphenonium.Approved
PancuroniumThe serum concentration of Trichlormethiazide can be increased when it is combined with Pancuronium.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Trichlormethiazide.Approved
ParecoxibThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Trichlormethiazide.Approved
ParicalcitolTrichlormethiazide may increase the hypercalcemic activities of Paricalcitol.Approved, Investigational
ParoxetineParoxetine may increase the hyponatremic activities of Trichlormethiazide.Approved, Investigational
PenbutololTrichlormethiazide may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trichlormethiazide.Approved, Vet Approved
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved, Vet Approved
PentoliniumThe serum concentration of Trichlormethiazide can be increased when it is combined with Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Trichlormethiazide.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Trichlormethiazide.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Trichlormethiazide.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Trichlormethiazide.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Trichlormethiazide.Approved, Withdrawn
PheniprazinePheniprazine may increase the hypotensive activities of Trichlormethiazide.Withdrawn
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Trichlormethiazide.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Trichlormethiazide.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Trichlormethiazide.Approved
PhenylbutazoneThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved, Withdrawn
PimecrolimusThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PinacidilTrichlormethiazide may increase the hypotensive activities of Pinacidil.Withdrawn
PindololPindolol may increase the hypotensive activities of Trichlormethiazide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Trichlormethiazide.Approved, Investigational
PipecuroniumThe serum concentration of Trichlormethiazide can be increased when it is combined with Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Trichlormethiazide.Approved
PirenzepineThe serum concentration of Trichlormethiazide can be increased when it is combined with Pirenzepine.Approved
PirfenidoneThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Pirfenidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Trichlormethiazide.Investigational
PirlindolePirlindole may increase the hypotensive activities of Trichlormethiazide.Approved
PiroxicamThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Piroxicam.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Trichlormethiazide.Withdrawn
PolythiazideTrichlormethiazide may increase the hypotensive activities of Polythiazide.Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Trichlormethiazide.Approved, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Trichlormethiazide.Approved, Nutraceutical
PrazosinPrazosin may increase the hypotensive activities of Trichlormethiazide.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Trichlormethiazide.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Trichlormethiazide.Experimental
PrimidonePrimidone may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved, Vet Approved
ProcaterolProcaterol may increase the hypokalemic activities of Trichlormethiazide.Approved
ProcyclidineThe serum concentration of Trichlormethiazide can be increased when it is combined with Procyclidine.Approved
PropacetamolThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Propacetamol.Approved
PropanthelineThe serum concentration of Trichlormethiazide can be increased when it is combined with Propantheline.Approved
PropiverineThe serum concentration of Trichlormethiazide can be increased when it is combined with Propiverine.Investigational
PropranololPropranolol may increase the hypotensive activities of Trichlormethiazide.Approved, Investigational
PTC299The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with PTC299.Investigational
QuinaprilQuinapril may increase the hypotensive activities of Trichlormethiazide.Approved, Investigational
QuinidineThe serum concentration of Trichlormethiazide can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Trichlormethiazide.Approved
RamiprilRamipril may increase the hypotensive activities of Trichlormethiazide.Approved
RasagilineRasagiline may increase the hypotensive activities of Trichlormethiazide.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trichlormethiazide.Approved
RemikirenRemikiren may increase the hypotensive activities of Trichlormethiazide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Trichlormethiazide.Approved, Investigational
RescinnamineTrichlormethiazide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Trichlormethiazide.Approved
ResveratrolThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Resveratrol.Experimental, Investigational
RilmenidineTrichlormethiazide may increase the hypotensive activities of Rilmenidine.Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Trichlormethiazide.Approved
RiociguatTrichlormethiazide may increase the hypotensive activities of Riociguat.Approved
RitodrineRitodrine may increase the hypokalemic activities of Trichlormethiazide.Approved
RituximabTrichlormethiazide may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Trichlormethiazide.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Trichlormethiazide.Withdrawn
SalbutamolSalbutamol may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Trichlormethiazide.Approved
SalsalateThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Salsalate.Approved
SaprisartanTrichlormethiazide may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Trichlormethiazide.Approved
ScopolamineThe serum concentration of Trichlormethiazide can be increased when it is combined with Scopolamine.Approved
Scopolamine butylbromideThe serum concentration of Trichlormethiazide can be increased when it is combined with Scopolamine butylbromide.Approved
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Trichlormethiazide.Approved, Investigational, Vet Approved
SelexipagTrichlormethiazide may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Seratrodast.Approved, Investigational
SertralineSertraline may increase the hyponatremic activities of Trichlormethiazide.Approved
SildenafilSildenafil may increase the antihypertensive activities of Trichlormethiazide.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Trichlormethiazide.Approved, Investigational
SitaxentanTrichlormethiazide may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SolifenacinThe serum concentration of Trichlormethiazide can be increased when it is combined with Solifenacin.Approved
SpiraprilTrichlormethiazide may increase the hypotensive activities of Spirapril.Approved
SRT501The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with SRT501.Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trichlormethiazide.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Sulindac.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Trichlormethiazide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Sulpiride.Approved
SuprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Suprofen.Approved, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Trichlormethiazide.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Trichlormethiazide.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Trichlormethiazide.Approved, Investigational
TemocaprilTrichlormethiazide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenoxicamThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tepoxalin.Vet Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Trichlormethiazide.Approved
TeriflunomideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Teriflunomide.Approved
TerlipressinTrichlormethiazide may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved, Vet Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Trichlormethiazide.Investigational
ThiopentalThiopental may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved, Vet Approved
Tiaprofenic acidThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tiaprofenic acid.Approved
TiboloneTrichlormethiazide may increase the hypotensive activities of Tibolone.Approved
TicrynafenTrichlormethiazide may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Trichlormethiazide.Approved
TinoridineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tinoridine.Investigational
TiotropiumThe serum concentration of Trichlormethiazide can be increased when it is combined with Tiotropium.Approved
TixocortolTixocortol may increase the hypokalemic activities of Trichlormethiazide.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Trichlormethiazide.Approved
TolazolineTolazoline may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Trichlormethiazide.Approved
Tolfenamic AcidThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Trichlormethiazide.Approved
TolterodineThe serum concentration of Trichlormethiazide can be increased when it is combined with Tolterodine.Approved, Investigational
TopiramateTrichlormethiazide may increase the hypokalemic activities of Topiramate.Approved
TorasemideTorasemide may increase the hypotensive activities of Trichlormethiazide.Approved
ToremifeneTrichlormethiazide may increase the hypercalcemic activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Trichlormethiazide.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Trichlormethiazide.Approved
TranilastThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Trichlormethiazide.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Trichlormethiazide.Approved
TravoprostTravoprost may increase the hypotensive activities of Trichlormethiazide.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Trichlormethiazide.Approved, Investigational
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrihexyphenidylThe serum concentration of Trichlormethiazide can be increased when it is combined with Trihexyphenidyl.Approved
TrimazosinTrichlormethiazide may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanThe serum concentration of Trichlormethiazide can be increased when it is combined with Trimethaphan.Approved
Trisalicylate-cholineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Trisalicylate-choline.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Trichlormethiazide.Withdrawn
TropicamideThe serum concentration of Trichlormethiazide can be increased when it is combined with Tropicamide.Approved
TrospiumThe serum concentration of Trichlormethiazide can be increased when it is combined with Trospium.Approved
TubocurarineThe serum concentration of Trichlormethiazide can be increased when it is combined with Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Trichlormethiazide.Approved, Investigational
UmeclidiniumThe serum concentration of Trichlormethiazide can be increased when it is combined with Umeclidinium.Approved
UnoprostoneTrichlormethiazide may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Trichlormethiazide.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Trichlormethiazide.Approved
VecuroniumThe serum concentration of Trichlormethiazide can be increased when it is combined with Vecuronium.Approved
VenlafaxineVenlafaxine may increase the hyponatremic activities of Trichlormethiazide.Approved
VilanterolVilanterol may increase the hypokalemic activities of Trichlormethiazide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Trichlormethiazide.Approved, Investigational
VinpocetineTrichlormethiazide may increase the hypotensive activities of Vinpocetine.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Trichlormethiazide.Approved, Investigational
XylometazolineTrichlormethiazide may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Trichlormethiazide.Approved, Vet Approved
ZaltoprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Zaltoprofen.Approved
ZileutonThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hyponatremic activities of Trichlormethiazide.Withdrawn
ZomepiracThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Zomepirac.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC03AA06C03AB06C03EA02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.2 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9356
Blood Brain Barrier-0.9431
Caco-2 permeable-0.7869
P-glycoprotein substrateNon-substrate0.6958
P-glycoprotein inhibitor INon-inhibitor0.8804
P-glycoprotein inhibitor IINon-inhibitor0.9432
Renal organic cation transporterNon-inhibitor0.8959
CYP450 2C9 substrateNon-substrate0.7173
CYP450 2D6 substrateNon-substrate0.8454
CYP450 3A4 substrateNon-substrate0.6828
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9454
CYP450 2D6 inhibitorNon-inhibitor0.9582
CYP450 2C19 inhibitorNon-inhibitor0.9611
CYP450 3A4 inhibitorNon-inhibitor0.9325
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9502
Ames testNon AMES toxic0.9209
CarcinogenicityNon-carcinogens0.844
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8282 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9721
hERG inhibition (predictor II)Non-inhibitor0.9276
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sanofi aventis us llc
  • Schering corp sub schering plough corp
  • Lannett co inc
  • Mm mast and co
  • Impax laboratories inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Tg united labs llc
  • Watson laboratories inc
Packagers
Dosage formsNot Available
Prices
Unit descriptionCostUnit
Trichlormethiazide powder15.0USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point270 dec °CPhysProp
water solubility800 mg/L (at 25 °C)MERCK (1989)
logP0.62SANGSTER (1994)
logS-2.68ADME Research, USCD
pKa8.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.415 mg/mLALOGPS
logP0.86ALOGPS
logP0.97ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)8.32ChemAxon
pKa (Strongest Basic)-4.1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.36 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity77.44 m3·mol-1ChemAxon
Polarizability31.97 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.06 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzothiadiazines. These are organic compounds containing a benzene fused to a thiadiazine ring (a six-member ring with two nitrogen atoms and a sulfur atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassThiadiazines
Sub ClassBenzothiadiazines
Direct ParentBenzothiadiazines
Alternative Parents
Substituents
  • Benzothiadiazine
  • Benzenesulfonamide
  • Secondary aliphatic/aromatic amine
  • Chlorobenzene
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Azacycle
  • Secondary amine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl chloride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A1
Uniprot ID:
Q13621
Molecular Weight:
121449.13 Da
References
  1. Li J, Wang DH: Function and regulation of epithelial sodium transporters in the kidney of a salt-sensitive hypertensive rat model. J Hypertens. 2007 May;25(5):1065-72. [PubMed:17414671 ]
  2. Hasannejad H, Takeda M, Taki K, Shin HJ, Babu E, Jutabha P, Khamdang S, Aleboyeh M, Onozato ML, Tojo A, Enomoto A, Anzai N, Narikawa S, Huang XL, Niwa T, Endou H: Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9. Epub 2003 Nov 10. [PubMed:14610216 ]
  3. Smith SM: Thiazide diuretics. N Engl J Med. 2010 Feb 18;362(7):659-60; author reply 660. [PubMed:20187262 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Steroid hormone binding
Specific Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.
Gene Name:
ATP1A1
Uniprot ID:
P05023
Molecular Weight:
112895.01 Da
References
  1. Takahashi N, Kondo Y, Fujiwara I, Ito O, Igarashi Y, Abe K: Characterization of Na+ transport across the cell membranes of the ascending thin limb of Henle's loop. Kidney Int. 1995 Mar;47(3):789-94. [PubMed:7752578 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name:
CA1
Uniprot ID:
P00915
Molecular Weight:
28870.0 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Molecular Weight:
29245.895 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid.
Gene Name:
CA4
Uniprot ID:
P22748
Molecular Weight:
35032.075 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Thiopurine s-methyltransferase activity
Specific Function:
Catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine.
Gene Name:
TPMT
Uniprot ID:
P51580
Molecular Weight:
28180.09 Da
References
  1. Lysaa RA, Giverhaug T, Wold HL, Aarbakke J: Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide. Eur J Clin Pharmacol. 1996;49(5):393-6. [PubMed:8866635 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23